Vertex Pharmaceuticals (BSP:VRTX34) Insider Ownership: 0.00 % (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:VRTX34 Vertex Pharmaceuticals Inc BSP:VRTX34
89 GF Score
Price R$87.58
GF Value R$82.59
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Insider Ownership?

Vertex Pharmaceuticals BSP:VRTX34 -0.07% 89 Insider Ownership is 0.00 % as of Aug. 20, 2026. GuruFocus rates BSP:VRTX34 with a GF Score™ of 89/100 and a GF Value™ of R$82.59 (Fairly Valued). The stock has 5 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vertex Pharmaceuticals's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vertex Pharmaceuticals's Institutional Ownership is 0.01%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vertex Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 98.57%.

Vertex Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Insider Ownership Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vertex Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:VRTX34
89GF Score
Vertex Pharmaceuticals Inc BSP:VRTX34
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Vertex Pharmaceuticals (BSP:VRTX34) has a Insider Ownership of 0.00 % as of Aug. 20, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Insider Ownership too high?
Vertex Pharmaceuticals' current Insider Ownership is 0.00 %. Overall, Vertex Pharmaceuticals has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Insider Ownership compare to REGN and RVMD?
Vertex Pharmaceuticals' Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (BSP:VRTX34) is currently considered Fairly Valued. The stock's GF Value™ is R$82.59, compared to a current price of R$87.58 — trading 6% above its estimated fair value. The current Insider Ownership is 0.00 %. Vertex Pharmaceuticals' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Vertex Pharmaceuticals (BSP:VRTX34), the current Insider Ownership is 0.00 % as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (BSP:VRTX34) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued. The current stock price of R$87.58 is trading 6% above its estimated GF Value™ of R$82.59. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for BSP:VRTX34:

  • Insider Ownership: 0.00 %
  • GF Value™: R$82.59 vs. price of R$87.58 (6% above fair value)
  • GF Score™: 89/100 with 5 warning signs

No single metric tells the full story. See the BSP:VRTX34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
89GF Score

Get the complete analysis for BSP:VRTX34

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$87.58
Price
R$82.59
GF Value